Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2017 16:01 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Proposed Public Offering of Common Stock

ROCKVILLE, Md., March 21, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
March 07, 2017 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights

IND for RGX-314 Phase I trial for wet AMD is active and dosing initiated for RGX-501 Phase I/II trial for HoFHInterim trial updates for RGX-314 and RGX-501 expected by year-end 2017 $159 million in...
March 07, 2017 16:03 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia

First AAV gene therapy treatment for HoFH; interim trial update expected late 2017 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage...
March 06, 2017 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference

ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
February 28, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
February 28, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO Honors Rare Disease Day® 2017

ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
February 14, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration

Six leading U.S. retinal surgery centers expected to participate as enrollment sites in the trialAnticipate beginning trial enrollment by mid-2017; interim trial update expected by the end of 2017 ...
February 09, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference

ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
February 02, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day

ROCKVILLE, Md., Feb. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
January 06, 2017 08:50 ET | Source: REGENXBIO Inc.

REGENXBIO Provides Year-End 2016 Corporate Update

Filed IND for RGX-314 Phase I clinical trial for wet AMDAnnounced initiation of protocol changes for RGX-501 Phase I/II clinical trial for HoFH; patient enrollment is now projected to begin first half...